THE IMPACT OF BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON THE COURSE OF RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE

被引：0
|
作者：
Avsar, A. Koken [1 ]
Can, G. [1 ]
Birlik, M. [1 ]
Sari, I. [1 ]
Onen, F. [1 ]
机构：
[1] Dokuz Eylul Univ, Dept Rheumatol, Med Sch, Izmir, Turkey
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.3440
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0099
引用
收藏
页码：624 / 625
页数：2
相关论文
共 50 条
  • [21] Use of disease-modifying anti-rheumatic drugs and cardiovascular events in patients with rheumatoid arthritis
    Kaminski, Matthew
    Shishehbor, Mehdi H.
    Gutierrez, Antonio
    Amini, Mohammad R.
    Coats, Walter
    Moghbelli, Meisam
    Askari, Arman T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A370 - A370
  • [22] Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs
    Meroni, P. L.
    Zavaglia, D.
    Girmenia, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (02) : 317 - 328
  • [23] Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
    Giachi, Andrea
    Cugno, Massimo
    Gualtierotti, Roberta
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [24] Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management
    Singh, Sukhbir
    Tiwary, Neha
    Sharma, Neelam
    Behl, Tapan
    Antil, Anita
    Anwer, Md. Khalid
    Ramniwas, Seema
    Sachdeva, Monika
    Elossaily, Gehan M.
    Gulati, Monica
    Ohja, Shreesh
    PHARMACEUTICALS, 2024, 17 (02)
  • [25] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Syngle, Ashit
    Kaur, Sudeep
    Verma, Inderjeet
    Syngle, Tanya
    Syngle, Vijaita
    CLINICAL RHEUMATOLOGY, 2017, 36 (08) : 1715 - 1720
  • [26] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Ashit Syngle
    Sudeep Kaur
    Inderjeet Verma
    Tanya Syngle
    Vijaita Syngle
    Clinical Rheumatology, 2017, 36 : 1715 - 1720
  • [27] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan
    PHARMACOLOGICAL RESEARCH, 2019, 148
  • [28] Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott, I. C.
    Kingsley, G. H.
    Scott, D. L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S4 - S8
  • [29] Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis
    Rodriguez-Rodriguez, L.
    Jover-Jover, J. A.
    Fontsere, O.
    Pena-Blanco, R. C.
    Leon, L.
    Fernandez-Gutierrez, B.
    Abasolo, L.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (06) : 433 - 436
  • [30] Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Enrique Machado-Alba, Jorge
    Felipe Ruiz, Andres
    Enrique Machado-Duque, Manuel
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2014, 36 (06): : 396 - 401
12345